{"drugs":["Nivolumab","Opdivo"],"mono":{"0":{"id":"931326-s-0","title":"Generic Names","mono":"Nivolumab"},"1":{"id":"931326-s-1","title":"Dosing and Indications","sub":[{"id":"931326-s-1-4","title":"Adult Dosing","mono":"<ul><li>Prior to administration, evaluate liver and thyroid function and serum creatinine, and monitor periodically during treatment.<\/li><li><b>Malignant melanoma, Unresectable or metastatic disease with progression following ipilimumab and a BRAF inhibitor (if BRAF V600 mutation-positive):<\/b> 3 mg\/kg IV infusion over 1 hour every 2 weeks until disease progression or unacceptable toxicity<\/li><li><b>Non-small cell lung cancer, Metastatic disease, after failure of prior platinum-based chemotherapy:<\/b> 3 mg\/kg IV infusion over 1 hour every 2 weeks until disease progression or unacceptable toxicity<\/li><\/ul>"},{"id":"931326-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy in pediatric patients not established."},{"id":"931326-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Renal toxicity, moderate to severe (grade 2 or 3), serum creatinine elevation greater than 1.5 and up to 6 times ULN or greater than 1.5 times baseline level:<\/b> Administer corticosteroids and withhold treatment until resolution to grade 0 or 1; if no improvement following corticosteroid treatment, resolution to grade 0 or 1 does not occur within 12 weeks, or worsening occurs (greater than 6 times ULN), permanently discontinue.<\/li><li><b>Renal toxicity, life-threatening serum creatinine elevation (grade 4):<\/b> Permanently discontinue.<\/li><li><b>Hepatic toxicity, moderate (grade 2), ALT or AST greater than 3 to up to 5 times ULN, or total bilirubin greater than 1.5 and up to 3 times ULN:<\/b> Administer corticosteroids and withhold treatment until resolution to grade 0 or 1; if resolution to grade 0 or 1 does not occur within 12 weeks, permanently discontinue.<\/li><li><b>Hepatic toxicity, severe (grade 3 or 4), ALT or AST greater than 5 times ULN, or total bilirubin greater than 3 times ULN:<\/b> Permanently discontinue.<\/li><li><b>Colitis, grade 2 or 3:<\/b> Administer corticosteroids and withhold treatment until resolution to grade 0 or 1; if resolution to grade 0 or 1 does not occur within 12 weeks, permanently discontinue.<\/li><li><b>Colitis, grade 4 or for recurrent colitis upon reinitiation:<\/b> Permanently discontinue.<\/li><li><b>Pneumonitis, grade 2:<\/b> Administer corticosteroids and withhold treatment until resolution to grade 0 or 1; if resolution to grade 0 or 1 does not occur within 12 weeks, permanently discontinue.<\/li><li><b>Pneumonitis, grade 3 or 4:<\/b> Permanently discontinue.<\/li><li><b>Treatment-related adverse event, grade 3 or severe:<\/b> Withhold treatment until resolution to grade 0 or 1 and consider reinitiation following corticosteroid treatment, based on severity of event; if reaction does not recover to grade 1 or completely resolve within 12 weeks or if event recurs following reinitiation, permanently discontinue.<\/li><\/ul>"},{"id":"931326-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Malignant melanoma, Unresectable or metastatic disease with progression following ipilimumab and a BRAF inhibitor (if BRAF V600 mutation-positive)<\/li><li>Non-small cell lung cancer, Metastatic disease, after failure of prior platinum-based chemotherapy<\/li><\/ul>"}]},"3":{"id":"931326-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931326-s-3-9","title":"Contraindications","mono":"Specific contraindications have not been determined <br\/>"},{"id":"931326-s-3-10","title":"Precautions","mono":"<ul><li>Endocrine and Metabolic:<\/li><li>-- Immune-mediated hypothyroidism and hyperthyroidism has been reported; monitoring recommended<\/li><li>Gastrointestinal:<\/li><li>-- Immune-mediated colitis has been reported; monitoring recommended and interruption or permanent discontinuation may be necessary<\/li><li>Hepatic:<\/li><li>-- Liver enzyme (ALT, AST, or bilirubin) elevations have been reported; monitoring recommended and interruption or discontinuation may be necessary<\/li><li>-- Immune-mediated hepatitis has been reported; monitoring recommended and interruption or permanent discontinuation may be necessary<\/li><li>Immunologic:<\/li><li>-- Clinically significant immune-mediated events (eg, pancreatitis, demyelination, autoimmune neuropathy, adrenal insufficiency, nerve paresis, diabetic ketoacidosis, Guillain-Barre syndrome, myasthenic syndrome) have been reported and may occur following treatment discontinuation; therapy interruption may be necessary<\/li><li>Renal:<\/li><li>-- Immune-mediated nephritis or renal dysfunction has been reported; monitoring recommended and interruption or permanent discontinuation may be necessary for serum creatinine elevation<\/li><li>Reproductive:<\/li><li>-- Pregnancy; fetal harm may occur; women of reproductive potential should use effective contraception during therapy and for 5 or more months after discontinuation<\/li><li>Respiratory:<\/li><li>-- Severe pneumonitis or interstitial lung disease, sometimes fatal, has been reported; monitoring recommended and interruption or discontinuation may be necessary<\/li><\/ul>"},{"id":"931326-s-3-11","title":"Pregnancy Category","mono":"Fetal risk has been demonstrated. (TH)<br\/>"},{"id":"931326-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"931326-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Pruritus (11% to 19%), Rash (16% to 21%; grades 3 or 4, 0.4% to 0.9%)<\/li><li><b>Endocrine metabolic:<\/b>Hyperkalemia (All grades, 15% to 18%; grades 3 or 4, 2% to 4.4%), Hyponatremia (All grades, 25% to 38%; grades 3 or 4, 5% to 10%)<\/li><li><b>Gastrointestinal:<\/b>Constipation (24%), Decrease in appetite (35%; grade 3 or 4, 2.6%), Nausea (29%; grade 3 or 4, 1.7%)<\/li><li><b>Hepatic:<\/b>Alkaline phosphatase raised (All grades, 14% to 22%; grades 3 or 4, 0% to 2.4%)<\/li><li><b>Musculoskeletal:<\/b>Musculoskeletal pain (36%; grade 3 or 4, 6%)<\/li><li><b>Respiratory:<\/b>Cough (17% to 32%), Upper respiratory infection (Up to 11%)<\/li><li><b>Other:<\/b>Fatigue (50%; grade 3 or 4, 7%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Vasculitis (Less than 2%)<\/li><li><b>Endocrine metabolic:<\/b>Adrenal insufficiency (Less than 2%), Diabetic ketoacidosis, Hypercalcemia (All grades, 20%; grades 3 or 4, 2.6%), Hyperthyroidism (1.7% to 3%), Hypophysitis, Hypopituitarism, Hypothyroidism (4.3% to 8%)<\/li><li><b>Gastrointestinal:<\/b>Colitis, Or diarrhea (21%; immune-mediated, 2.2%), Pancreatitis (Less than 2%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised (All grades, 12% to 16%; grades 3 or 4, 0% to 1.6%), AST\/SGOT level raised (All grades, 16% to 28%; grades 3 or 4, 0.9% to 2.4%), Hepatitis (Immune-mediated, 1.1%), Serum bilirubin raised (2.7% to 9%)<\/li><li><b>Musculoskeletal:<\/b>Abducens nerve palsy, And facial (Less than 1%), Eaton-Lambert syndrome<\/li><li><b>Neurologic:<\/b>Demyelination of spinal cord (Less than 2%), Guillain-Barr  syndrome, Motor dysfunction (Less than 2%), Neurological muscle weakness (Less than 2%), Neuropathy, Autoimmune (Less than 2%)<\/li><li><b>Ophthalmic:<\/b>Uveitis (Less than 2%)<\/li><li><b>Renal:<\/b>Nephritis, Or renal dysfunction (Immune-mediated, 0.7% to 0.9%), Serum creatinine raised (13% to 22%)<\/li><li><b>Respiratory:<\/b>Chronic obstructive pulmonary disease, Exacerbation (2% or greater), Dyspnea (38%; grade 3 or 4, 9%), Hemoptysis (2% or greater), Pleural effusion (2% or greater), Pneumonia (10%; grade 3 or 4, 5%), Pneumonitis (3.4% to 6%; immune-mediated pneumonitis, 2.2%)<\/li><li><b>Other:<\/b>Pain (10%; grade 3 or 4, 2.6%)<\/li><\/ul>"},"6":{"id":"931326-s-6","title":"Drug Name Info","sub":{"0":{"id":"931326-s-6-17","title":"US Trade Names","mono":"Opdivo<br\/>"},"2":{"id":"931326-s-6-19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"931326-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"931326-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"931326-s-7","title":"Mechanism Of Action","mono":"Nivolumab is a monoclonal antibody that enhances the antitumor response by binding to PD-1 receptors and blocking its interaction with PD-L1 and PD-L2. In mouse models blocking PD-1 activity resulted in decreased tumor growth.<br\/>"},"8":{"id":"931326-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"931326-s-8-24","title":"Distribution","mono":"Vd: 8 L <br\/>"},"3":{"id":"931326-s-8-26","title":"Excretion","mono":"Total body clearance: 9.5 mL\/hr <br\/>"},"4":{"id":"931326-s-8-27","title":"Elimination Half Life","mono":"26.7 days <br\/>"}}},"9":{"id":"931326-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>Withdraw desired volume from vial and dilute in either NS or D5W to a final concentration of 1 to 10 mg\/mL.<\/li><li>Gently invert to mix; do not shake.<\/li><li>Discard unused portions of vial.<\/li><li>Do not freeze.<\/li><li>If stored at room temperature, administer within 4 hours, including preparation and infusion time; if stored under refrigeration (2 to 8 degrees C or 36 to 46 degrees F), administer within 24 hours.<\/li><li>Infuse over 1 hour via a sterile, nonpyrogenic, low protein-binding, inline filter with a pore size of 0.2 to 1.2 mcm.<\/li><li>Do not infuse other drugs via the same IV line.<\/li><li>Flush line following infusion.<\/li><\/ul>"},"10":{"id":"931326-s-10","title":"Monitoring","mono":"<ul><li>Reduction in tumor growth may indicate efficacy<\/li><li>Liver function tests; prior to and periodically during treatment<\/li><li>Serum creatinine levels; prior to and periodically during treatment<\/li><li>Thyroid function; prior to and periodically during treatment<\/li><li>Signs and symptoms of pneumonitis<\/li><li>Signs and symptoms of immune-mediated colitis<\/li><\/ul>"},"11":{"id":"931326-s-11","title":"How Supplied","mono":"<b>Opdivo<\/b><br\/>Intravenous Solution: 10 MG\/ML<br\/>"},"13":{"id":"931326-s-13","title":"Clinical Teaching","mono":"<ul><li>Recommend patient use reliable contraception to avoid pregnancy during therapy and at least 5 months post-treatment.<\/li><li>Side effects include rash, pruritus, cough, upper respiratory tract infection, and peripheral edema.<\/li><li>Instruct patient to immediately report signs\/symptoms of pneumonitis (new or worsening cough, chest pain, shortness of breath).<\/li><li>Advise patient to immediately report signs\/symptoms of colitis (diarrhea or severe abdominal pain).<\/li><li>Instruct patient to immediately report signs\/symptoms of hepatitis (jaundice, severe nausea or vomiting, abdominal pain on right side, lethargy, easy bruising or bleeding).<\/li><li>Inform patient to immediately report signs\/symptoms of nephritis (decreased urine output, blood in urine, swelling of ankles, loss of appetite) or any other symptoms of renal dysfunction.<\/li><li>Advise patient to immediately report signs\/symptoms of hypothyroidism or hyperthyroidism.<\/li><\/ul>"}}}